Inovio Pharmaceuticals, Inc. — Q1 2014 Form 10-Q
Business context and reporting period. The filing covers the unaudited quarter ended March 31, 2014, compared with Q1 2013. Inovio is developing DNA-based vaccines and immune therapies, including electroporation delivery technology. It had no approved human products and reported no product-sales revenue; revenue came from collaborations, grants and other sources. The filing’s index refers to a period ended March 31, 2013, but the financial statements and cover identify March 31, 2014.
Financial performance and liquidity
| Metric | Q1 2014 / March 31, 2014 | Comparable period / prior year-end |
|---|---|---|
| Total revenue | $2.36 million | $1.46 million in Q1 2013 |
| Operating expenses | $12.36 million | $8.09 million in Q1 2013 |
| Operating loss | $10.00 million | $6.63 million in Q1 2013 |
| Net loss attributable to Inovio | $10.82 million; $0.05 per share | $8.84 million; $0.06 per share in Q1 2013 |
| Cash and cash equivalents | $98.77 million | $33.72 million at December 31, 2013 |
| Short-term investments | $18.01 million | $18.91 million at December 31, 2013 |
| Working capital | $106.0 million | $29.7 million at December 31, 2013 |
| Operating cash flow | $(5.56) million | $(5.13) million in Q1 2013 |
| Total liabilities | $22.48 million | $35.38 million at December 31, 2013 |
Revenue was about $0.90 million higher year over year, principally reflecting the Roche collaboration; grant and miscellaneous revenue declined. Research and development expense rose to $8.23 million from $5.12 million, and general and administrative expense increased to $4.13 million from $2.97 million. The filing reports no conventional borrowing balance in the presented balance sheet; current liabilities include $6.05 million of warrant liabilities. Cash flows from financing were $69.89 million, mainly from equity financing and warrant and option exercises.
Material changes and notable items
- In March 2014, Inovio sold 21.81 million common shares at $2.90 per share, raising approximately $59.2 million net. It also received $10.7 million from warrant and option exercises, including $9.4 million from exercise of January 2011 financing warrants.
- Roche revenue recognized in Q1 was approximately $1.4 million, primarily allocated to the INO-5150 and INO-1800 licenses. The company reported $3.6 million of deferred revenue related to the Roche agreement at quarter-end. The agreement provides for up to $412.5 million in additional development, regulatory and commercial event-based payments, plus potential royalties; no event-based payments or milestones were achieved in the quarter.
- Stock-based compensation increased substantially: employee compensation cost was $2.13 million versus $0.45 million in Q1 2013. The change in fair value of common stock warrants was a $0.51 million expense, compared with a $1.43 million expense in Q1 2013.
- Inovio entered an 11.5-year office lease, with future minimum payments of $14.10 million; it expected to occupy the space beginning in Q3 2014 and sublet its existing facility.
Outlook, commentary and risks
Management expected continued substantial operating losses as it funds research, preclinical work, clinical trials and regulatory activities. It believed cash, cash equivalents and short-term investments were sufficient for planned working capital requirements through the end of 2017, but stated it would rely on outside financing beyond that period. No specific revenue or earnings guidance was provided. Management cautioned that quarterly results are not necessarily indicative of future results.
Key risks include the early-stage and uncertain nature of clinical development, potential failure to demonstrate safety or efficacy or obtain regulatory approval, manufacturing and trial delays, dependence on collaborators and government funding, limited revenue sources, future financing needs and potential dilution. The company had an accumulated deficit of $306.6 million. It disclosed no material change to the risk factors in its 2013 Form 10-K and no legal proceedings applicable to this filing. Management reported disclosure controls were effective as of March 31, 2014, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether clinical progress, trial outcomes and regulatory milestones support the company’s development programs; all human product candidates remained in research and development.
- Whether the stated cash runway through 2017 remains achievable given operating cash use, planned trial spending and other commitments.
- How much future revenue and funding will depend on Roche, government grants and other collaborators, and whether any contractual milestones are achieved.
- The effects of equity issuance, warrant exercises and stock-based compensation on share count and dilution; 240.63 million shares were outstanding on May 2, 2014.
- The assumptions behind Level 3 warrant valuations and the impact of the new lease’s long-term payment commitments.